ClinicalTrials.gg
CompletedNCT00330759Updated Nov 7, 2022Results posted

Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.

A Phase 3 interventional study of Denosumab and Zoledronic Acid in Bone Metastases, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-07.

Sponsored by Amgen · Phase 3, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,779
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 43 studies in Multiple Myeloma by Amgen — none open to participants now, none under way, none of them phase 3. Multiple Myeloma · Amgen.

Enrollment
Largest of 40
1,779 · median 101
Started
2006
the only one that year
Phase 3
11 of 43
none open now
Registered
5th of 43
by date

Among the 43 studies in Multiple Myeloma by Amgen, this one has the largest enrollment of the 40 interventional ones that give a count, is the only one that started in 2006, is one of 11 in phase 3, and was the 5th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

None of the 43 studies in Multiple Myeloma by Amgen is open now. The open studies under Multiple Myeloma, anywhere →

Who these studies take

Of the 584 Multiple Myeloma studies recruiting now, 429 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 43 studies in Multiple Myeloma by Amgen as a file.
02

Study summary

The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid (Zometa®) in the treatment of bone metastases (lytic bone lesions from multiple myeloma) in subjects with advanced cancer and multiple myeloma (excluding breast and prostate cancer)

03

Conditions studied

  • Bone Metastases

Keywords

  • Bone metastases
  • lytic bone lesions
  • advanced cancer
  • multiple myeloma
  • lymphoma
  • solid tumors
  • skeletal related events
  • skeletal fractures
  • spinal cord compressions, radiation to bone
  • surgery to bone, bisphosphonates
  • denosumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults with histologically/cystologically confirmed advanced cancers including solid tumors, multiple myeloma, and lymphoma
  • Radiographic evidence of at least one bone (or lytic bone lesion from multiple myeloma); performance status 0, 1, or 2
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of breast or prostate cancer
  • Current or prior intravenous bisphosphonate administration
  • Current or prior oral bisphosphonates for bone , of less than 6 months
  • Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,779 participants (actual)

Study arms

  • Active comparator
    zoledronic acid

    denosumab placebo with active zoledronic acid

    Drug: Zoledronic Acid

  • Experimental
    denosumab

    active denosumab with zoledronic acid placebo

    Biological: Denosumab

Interventions

  • BiologicalDenosumab

    120 milligrams by subcutaneous injection every 4 weeks

  • 4 milligrams intravenous Zoledronic Acid over minimum 15 minutes every 4 weeks

    Also known as: Zometa

06

What researchers measure

Primary outcomes

  1. Time to the First On-Study Skeletal-Related Event (Non-Inferiority)

    Time to the first on-study skeletal-related event (SRE) using a non-inferiority analysis. Median was estimated using the Kaplan-Meier method.

    Time frame: up to 33 months

Secondary outcomes

  1. Time to First On-Study Skeletal-Related Event (Superiority)

    Time to first on-study skeletal-related event (SRE) using a test for superiority. Median was estimated using the Kaplan-Meier method.

    Time frame: up to 33 months

  2. Time to the First-and-Subsequent On-Study Skeletal-Related Event

    Time to the first-and-subsequent on-study skeletal-related event (SRE) using multiple event analysis. To be considered a subsequent SRE, the event must occur at least 21 days after the previous SRE. This outcome measure utilizes multiple event times, was analyzed based on a proportional mean model, and is therefore more appropriately summarized by the cumulative mean number of events.

    Time frame: up to 33 months

07

Results

Posted Apr 9, 2014

Participant flow

Participants were enrolled from 21 June 2006 through 16 May 2008

Participant flow — Overall Study
MilestoneZoledronic AcidDenosumab
Started890886
Received investigational product878878
Completed178180
Not completed712706
Withdrew: Death316310
Withdrew: Disease progression104126
Withdrew: Withdrawal by subject143124
Withdrew: Adverse event4836
Withdrew: Participant request3122
Withdrew: Lost to follow-up1622
Withdrew: Noncompliance1517
Withdrew: Physician decision12
Withdrew: Protocol deviation02
Withdrew: Ineligibility determined21
Withdrew: Other3644

Outcome measures

PrimaryTime to the First On-Study Skeletal-Related Event (Non-Inferiority)

Time to the first on-study skeletal-related event (SRE) using a non-inferiority analysis. Median was estimated using the Kaplan-Meier method.

Time frame:
up to 33 months
Reported as:
Median · Days
Time to the First On-Study Skeletal-Related Event (Non-Inferiority)
DaysZoledronic AcidDenosumab
Time to the First On-Study Skeletal-Related Event (Non-Inferiority)496.0 (371.00 to 589.00)625.0 (456.00 to NA)
Statistical analysis
  • Zoledronic Acid vs Denosumab · Regression, Cox · p = 0.0007 · Hazard ratio (hr): 0.84 · 95% CI 0.71 to 0.98Stratified by tumor type, previous skeletal-related event, and systematic anti-cancer therapy
SecondaryTime to First On-Study Skeletal-Related Event (Superiority)

Time to first on-study skeletal-related event (SRE) using a test for superiority. Median was estimated using the Kaplan-Meier method.

Time frame:
up to 33 months
Reported as:
Median · Days
Time to First On-Study Skeletal-Related Event (Superiority)
DaysZoledronic AcidDenosumab
Time to First On-Study Skeletal-Related Event (Superiority)496.0 (371.00 to 589.00)625.0 (456.00 to NA)
Statistical analysis
  • Zoledronic Acid vs Denosumab · Regression, Cox · p = 0.060 · Hazard ratio (hr): 0.84 · 95% CI 0.71 to 0.98Stratified by tumor type, previous skeletal-related event, and systematic anti-cancer therapy
SecondaryTime to the First-and-Subsequent On-Study Skeletal-Related Event

Time to the first-and-subsequent on-study skeletal-related event (SRE) using multiple event analysis. To be considered a subsequent SRE, the event must occur at least 21 days after the previous SRE. This outcome measure utilizes multiple event times, was analyzed based on a proportional mean model, and is therefore more appropriately summarized by the cumulative mean number of events.

Time frame:
up to 33 months
Reported as:
Number · Events
Time to the First-and-Subsequent On-Study Skeletal-Related Event
EventsZoledronic AcidDenosumab
Time to the First-and-Subsequent On-Study Skeletal-Related Event436392
Statistical analysis
  • Zoledronic Acid vs Denosumab · Anderson-Gill model · p = 0.145 · Hazard ratio (hr): 0.90 · 95% CI 0.77 to 1.04Stratified by tumor type, previous skeletal-related event, and systematic anti-cancer therapy

Adverse events

Collected over up to 2 years 9 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zoledronic Acid 4 mg Q4W—581/878 (66.2%)767/878 (87.4%)
Denosumab 120 mg Q4W—552/878 (62.9%)751/878 (85.5%)
Most frequent serious events
Showing 10 of 549
Most frequent serious events
EventZoledronic Acid 4 mg Q4WDenosumab 120 mg Q4W
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)100/878103/878
DyspnoeaRespiratory, thoracic and mediastinal disorders54/87855/878
PneumoniaInfections and infestations44/87852/878
AnaemiaBlood and lymphatic system disorders49/87825/878
Respiratory failureRespiratory, thoracic and mediastinal disorders40/87845/878
Metastases to central nervous systemNeoplasms benign, malignant and unspecified (incl cysts and polyps)44/87843/878
General physical health deteriorationGeneral disorders38/87826/878
DehydrationMetabolism and nutrition disorders34/87835/878
Febrile neutropeniaBlood and lymphatic system disorders31/87821/878
Spinal cord compressionNervous system disorders26/87827/878
Most frequent other events
Showing 10 of 42
Most frequent other events
EventZoledronic Acid 4 mg Q4WDenosumab 120 mg Q4W
AnaemiaBlood and lymphatic system disorders264/878234/878
NauseaGastrointestinal disorders260/878244/878
FatigueGeneral disorders216/878203/878
ConstipationGastrointestinal disorders209/878188/878
DyspnoeaRespiratory, thoracic and mediastinal disorders171/878193/878
AnorexiaMetabolism and nutrition disorders190/878163/878
Back painMusculoskeletal and connective tissue disorders183/878169/878
VomitingGastrointestinal disorders167/878174/878
CoughRespiratory, thoracic and mediastinal disorders151/878172/878
AstheniaGeneral disorders171/878156/878

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Zoledronic AcidDenosumabTotal
Mean60.6 ± 10.759.3 ± 11.459.9 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)Zoledronic AcidDenosumabTotal
Female338298636
Male5525881140
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Zoledronic AcidDenosumabTotal
White or Caucasian7707701540
Black or African American292049
Hispanic or Latino364985
Asian443680
Japanese134
American Indian or Alaska Native202
Other8816
Tumor Type Stratification Factor
Tumor Type Stratification Factor(Participants)Zoledronic AcidDenosumabTotal
Multiple myeloma9386179
Other452457909
Non-small cell lung cancer345343688
Previous Skeletal-Related Event Stratification Factor
Previous Skeletal-Related Event Stratification Factor(Participants)Zoledronic AcidDenosumabTotal
Yes446440886
No444446890
Systematic Anti-Cancer Therapy Stratification Factor
Systematic Anti-Cancer Therapy Stratification Factor(Participants)Zoledronic AcidDenosumabTotal
Yes7477461493
No143140283
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Henry D, Vadhan-Raj S, Hirsh V, von Moos R, Hungria V, Costa L, Woll PJ, Scagliotti G, Smith G, Feng A, Jun S, Dansey R, Yeh H. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer. 2014 Mar;22(3):679-87. doi: 10.1007/s00520-013-2022-1. Epub 2013 Oct 26. PubMed 24162260 ↗
  • Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011 Mar 20;29(9):1125-32. doi: 10.1200/JCO.2010.31.3304. Epub 2011 Feb 22. PubMed 21343556 ↗
  • Scagliotti GV, Hirsh V, Siena S, Henry DH, Woll PJ, Manegold C, Solal-Celigny P, Rodriguez G, Krzakowski M, Mehta ND, Lipton L, Garcia-Saenz JA, Pereira JR, Prabhash K, Ciuleanu TE, Kanarev V, Wang H, Balakumaran A, Jacobs I. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol. 2012 Dec;7(12):1823-1829. doi: 10.1097/JTO.0b013e31826aec2b. PubMed 23154554 ↗
  • Vadhan-Raj S, von Moos R, Fallowfield LJ, Patrick DL, Goldwasser F, Cleeland CS, Henry DH, Novello S, Hungria V, Qian Y, Feng A, Yeh H, Chung K. Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid. Ann Oncol. 2012 Dec;23(12):3045-3051. doi: 10.1093/annonc/mds175. Epub 2012 Jul 31. PubMed 22851406 ↗
  • Abdel-Rahman O. Predictors of skeletal-related events among cancer patients with bone metastases treated with zoledronic acid: a secondary analysis of a randomized study. Expert Opin Drug Saf. 2018 Aug;17(8):757-761. doi: 10.1080/14740338.2018.1497157. Epub 2018 Jul 11. PubMed 29972647 ↗
  • Body JJ, Bone HG, de Boer RH, Stopeck A, Van Poznak C, Damiao R, Fizazi K, Henry DH, Ibrahim T, Lipton A, Saad F, Shore N, Takano T, Shaywitz AJ, Wang H, Bracco OL, Braun A, Kostenuik PJ. Hypocalcaemia in patients with metastatic bone disease treated with denosumab. Eur J Cancer. 2015 Sep;51(13):1812-21. doi: 10.1016/j.ejca.2015.05.016. Epub 2015 Jun 17. PubMed 26093811 ↗
  • Diel IJ, Body JJ, Stopeck AT, Vadhan-Raj S, Spencer A, Steger G, von Moos R, Goldwasser F, Feng A, Braun A. The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Eur J Cancer. 2015 Jul;51(11):1467-75. doi: 10.1016/j.ejca.2015.04.017. Epub 2015 May 11. PubMed 25976743 ↗
  • von Moos R, Body JJ, Egerdie B, Stopeck A, Brown JE, Damyanov D, Fallowfield LJ, Marx G, Cleeland CS, Patrick DL, Palazzo FG, Qian Y, Braun A, Chung K. Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Support Care Cancer. 2013 Dec;21(12):3497-507. doi: 10.1007/s00520-013-1932-2. Epub 2013 Aug 22. PubMed 23975226 ↗
  • Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012 Nov;48(16):3082-92. doi: 10.1016/j.ejca.2012.08.002. Epub 2012 Sep 10. PubMed 22975218 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2006 to primary completion in Apr 2009, 34 months.

Results were first posted in Apr 2014, 5 years after primary completion. A results delay was requested in Jun 2010.

Of 108 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 34 months is below that.

Counting every sponsor, half of 180 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2006
First posted
May 29, 2006
StartActual
Jun 1, 2006
Primary completionActual
Apr 1, 2009
CompletionActual
Oct 1, 2011
Results delay requested
Jun 29, 2010
Results first posted
Apr 9, 2014
Last update
Nov 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00330759
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
May 29, 2006
Start date
Jun 1, 2006
Primary completion
Apr 1, 2009
Completion
Oct 1, 2011
Results posted
Apr 9, 2014
Last update
Nov 7, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion